Purpose: To assess dynamic tumor tracking (DTT) target localization uncertainty for in-vivo marker-based stereotactic ablative radiotherapy (SABR) treatments of the liver using electronic-portal-imaging-device (EPID) images. The Planning Target Volume (PTV) margin contribution for DTT is estimated.
Methods: Phantom and patient EPID images were acquired during non-coplanar 3DCRT-DTT delivered on a Vero4DRT linac. A chain-code algorithm was applied to detect Multileaf Collimator (MLC)-defined radiation field edges. Gold-seed markers were detected using a connected neighbor algorithm. For each EPID image, the absolute differences between the measured center-of-mass (COM) of the markers relative to the aperture-center (Tracking Error, (E )) was reported in pan, tilt, and 2D-vector directions at the isocenter-plane.
Phantom Study: An acrylic cube phantom implanted with gold-seed markers was irradiated with non-coplanar 3DCRT-DTT beams and EPID images collected. Patient Study: Eight liver SABR patients were treated with non-coplanar 3DCRT-DTT beams. All patients had three to four implanted gold-markers. In-vivo EPID images were analyzed.
Results: Phantom Study: On the 125 EPID images collected, 100% of the markers were identified. The average ± SD of E were 0.24 ± 0.21, 0.47 ± 0.38, and 0.58 ± 0.37 mm in pan, tilt and 2D directions, respectively. Patient Study: Of the 1430 EPID patient images acquired, 78% had detectable markers. Over all patients, the average ± SD of E was 0.33 ± 0.41 mm in pan, 0.63 ± 0.75 mm in tilt and 0.77 ± 0.80 mm in 2D directions The random 2D-error, σ, for all patients was 0.79 mm and the systematic 2D-error, Σ, was 0.20 mm. Using the Van Herk margin formula 1.1 mm planning target margin can represent the marker based DTT uncertainty.
Conclusions: Marker-based DTT uncertainty can be evaluated in-vivo on a field-by-field basis using EPID images. This information can contribute to PTV margin calculations for DTT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338758 | PMC |
| http://dx.doi.org/10.1002/acm2.13969 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Feasibility of reconstructing in-vivo patient 3D dose distributions from 2D EPID image data using convolutional neural networks.
Phys Med Biol
December 2024
School of Nuclear Science and Technology, University of Science and Technology of China, No.96, JinZhai Road Baohe District, Hefei, Anhui, China, Hefei, 230026, CHINA.
The primary purpose of this work is to demonstrate the feasibility of a deep convolutional neural network (dCNN) based algorithm that uses two-dimensional (2D) EPID images and CT images as input to reconstruct 3D dose distributions inside the patient. Approach: To generalize dCNN training and testing data, geometric and materials models of a VitalBeam accelerator treatment head and a corresponding EPID imager were constructed in detail in the GPU-accelerated Monte Carlo dose computing software, ARCHER. The EPID imager pixel spatial resolution ranging from 1.
View Article and Find Full Text PDFDevelopment of a new VMAT QA framework for Mobius3D using control-point specific EPID images.
Front Oncol
December 2024
Medical Physics and Biomedical Engineering Lab (MPBEL), Yonsei University College of Medicine, Seoul, Republic of Korea.
Purpose: This study presents novel quality assurance (QA) approach for volumetric modulated arc therapy (VMAT) that leverages frame-by-frame electronic portal imaging device (EPID) images integrated into Mobius3D for accurate three-dimensional dose calculations.
Methods: Sequential EPID images for VMAT plans were acquired every 0.4-second by iView system and processed through iterative deconvolution to mitigate blurring from photon scattering.
The evolving role of MRI in the detection of extrathyroidal extension of papillary thyroid carcinoma: a systematic review and meta-analysis.
BMC Cancer
December 2024
Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Background: Papillary thyroid carcinoma (PTC) is the predominant form of thyroid cancer, and the presence of extrathyroidal extension (ETE) significantly impacts treatment decisions and prognosis. Accurate preoperative detection of ETE remains challenging, highlighting the need to evaluate advanced imaging techniques.This systematic review and meta-analysis aimed to investigate the diagnostic accuracy of magnetic resonance imaging (MRI) in detecting extrathyroidal extension (ETE) among patients diagnosed with papillary thyroid carcinoma (PTC).
View Article and Find Full Text PDFTocilizumab in cranial and extracranial giant cell arteritis: a national multicenter study of 471 cases.
Rheumatology (Oxford)
December 2024
Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain.
Objective: The spectrum of giant cell arteritis (GCA) includes different vascular phenotypes. Tocilizumab (TCZ) is the only biologic currently approved regardless these phenotypes. We aimed to assess the effectiveness of TCZ in different phenotypes.
View Article and Find Full Text PDFFeasibility study of structural similarity index for patient-specific quality assurance.
J Appl Clin Med Phys
December 2024
Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, South Korea.
Background: The traditional gamma evaluation method combines dose difference (DD) and distance-to-agreement (DTA) to assess the agreement between two dose distributions. However, while gamma evaluation can identify the location of errors, it does not provide information about the type of errors.
Purpose: The purpose of this study is to optimize and apply the structural similarity (SSIM) index algorithm as a supplementary metric for the quality evaluation of radiation therapy plans alongside gamma evaluation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!